Voyage Phase 3 Trial Achieves Primary and Key Secondary Endpoints

Definium Therapeutics (DFTX) announced that its Phase 3 Voyage trial (NCT06741228), conducted across approximately 35 U.S. sites, achieved its primary endpoint in 214 adult patients with Generalized Anxiety Disorder (GAD) who were randomized 1:1. The investigational drug, DT120 ODT (lysergide tartrate), is an orally disintegrating tablet formulation of LSD and a serotonin 2A (5-HT2A) receptor partial agonist, administered as a single 100-microgram dose. At week 12, the mean change from baseline on the HAM-A scale was -11.6 in the treatment group and -6.2 in the placebo group, resulting in a placebo-adjusted difference of -5.4 and a p-value of <0.0001, with a Cohen's d of 0.81. This not only demonstrates statistical significance but also indicates that a single-dose treatment for a psychiatric disorder has replicated a large standardized effect size in a confirmatory trial.

Differentiation Lies in Onset Within Two Days and 12-Week Duration

DT120 demonstrated efficacy as early as day 2 after administration, which was sustained through week 12. The placebo-adjusted difference on the HAM-A scale at week 1 was 7.7, meeting all key secondary endpoints. At week 12, response rates were 43% versus 16%, remission rates were 14% versus 4%, and rates of achieving a score of mild or less were 51% versus 23%. Treatment-related adverse events were primarily mild to moderate and occurred mainly on the day of administration, with no new safety signals or signals of suicidal behavior observed. The median time to discharge criteria was 6.4 hours, and 92% of patients met the criteria within 8 hours, quantifying a key cost factor for commercialization: the length of stay in healthcare facilities.

A Different Commercial Model Compared to Daily Standard Treatments

The current standard of care includes Lexapro (escitalopram, SSRI), Paxil (paroxetine, SSRI), Effexor XR (venlafaxine, SNRI), and Cymbalta (duloxetine, SNRI), all of which are FDA-approved and marketed. These medications require continuous use and are associated with delayed onset of action, discontinuation symptoms, and sexual dysfunction, leading to frequent treatment changes and discontinuations. DT120, on the other hand, is being developed as a single-dose treatment, potentially without the need for adjunctive psychotherapy. However, the potential for hallucinogenic effects raises concerns about functional unblinding (where patients can guess their treatment assignment) and the need for supervised administration for at least 6 hours, which are key variables for real-world clinical adoption. The second Phase 3 GAD trial, Panorama, includes a 50-microgram active control arm to address these issues, with topline results expected in September 2026.

Regulatory Value and Market Opportunity

The FDA granted DT120 (then known as MM120) Breakthrough Therapy Designation for GAD on March 4, 2024, but the drug is currently in Phase 3 development and has not yet reached the stage of FDA, EMA, or PMDA approval, or an FDA Advisory Committee (AdComm) vote. The last FDA approval for a new drug for GAD in the U.S. was Cymbalta on February 26, 2007, and the success of the Voyage trial has the potential to revitalize innovation in this area after approximately 19 years. The global GAD market is projected to grow from USD 2.50 billion in 2026 to USD 3.48 billion in 2032, and the company estimates the U.S. patient population to be approximately 26 million. If Panorama replicates the efficacy and addresses the unblinding concerns, DT120 could offer a distinct advantage over existing SSRIs and SNRIs, as well as other GAD drugs in development, such as ulotaront, ITI-1284, and ABBV-932, in terms of dosing frequency and mechanism of action.